Lamivudine + ZidovudineThird Party Manufacturing in India

Lamivudine and Zidovudine are both nucleoside reverse transcriptase inhibitors (NRTIs) that work synergistically to suppress HIV replication. Zidovudine, a thymidine analogue, is phosphorylated intracellularly to its active triphosphate form which competes with the natural substrate thymidine triphosphate for incorporation into viral DNA. Once incorporated, the azido group prevents the formation of the 5′-3′ phosphodiester bond, causing chain termination. Lamivudine, a cytidine analogue, undergoes similar intracellular phosphorylation and its active metabolite competes with cytidine triphosphate for incorporation into the growing viral DNA strand. The absence of a 3′-hydroxyl group in lamivudine's oxathiolane ring prevents further nucleotide addition, effectively halting DNA chain elongation. This dual inhibition targets HIV reverse transcriptase at two distinct points, reducing the likelihood of resistance development compared to monotherapy. The combination is especially effective because the resistance profiles of the two drugs do not fully overlap, allowing sustained viral suppression when used together. Both drugs show activity against HIV-1 and HIV-2 and are well absorbed orally, making this fixed-dose combination a cornerstone of antiretroviral therapy worldwide.

Therapeutic Uses

Lamivudine + Zidovudine is prescribed for the treatment of:

• HIV-1 Infection in Adults and Children: As part of combination antiretroviral therapy (ART) to reduce viral load and increase CD4 cell counts.
• Prevention of Mother-to-Child Transmission (PMTCT): Used during pregnancy and labour to reduce the risk of vertical HIV transmission.
• Post-Exposure Prophylaxis (PEP): Following occupational or non-occupational exposure to HIV, in combination with a third agent.
• HIV-2 Infection: Both drugs retain activity against HIV-2 and are used where first-line NNRTI-based regimens are not suitable.

Why Manufacturers Choose Lamivudine + Zidovudine

This fixed-dose combination is one of the most widely prescribed antiretroviral therapies globally, ensuring consistent bulk demand from national ART programmes and international procurement agencies. The combination is included in the WHO Essential Medicines List and remains a first-line option in many low- and middle-income countries. Indian manufacturers benefit from well-established API supply chains,成熟的 formulation technology, and high-volume export opportunities to African and Asian markets. The combination's proven safety profile and predictable pharmacokinetics make it an ideal candidate for third party manufacturing, with stable regulatory pathways across WHO-prequalified, USFDA, and MHRA frameworks.

This makes Lamivudine + Zidovudine one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.